GS Investments’s CRISPR Therapeutics CRSP Stock Holding History

GS Investments’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$273	Hold	5	–	–	﹤0.01%	131
2026 Q1	$238	Buy	+5	New	+$264	﹤0.01%	130

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GS Investments's CRSP Position: Q2 2026 in Review

GS Investments held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 5 shares worth $273. The position accounts for ﹤0.01% of the portfolio, ranked #131.

GS Investments first reported a position in CRSP in Q1 2026 and has held it in 2 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

GS Investments held 5 shares of CRISPR Therapeutics worth $273 as of Q2 2026.
GS Investments left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of GS Investments's portfolio in Q2 2026, its #131 holding.
GS Investments first reported a position in CRISPR Therapeutics in Q1 2026 and has held it in 2 quarters since.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on GS Investments's 13F filing for Q2 2026, filed 6 Aug 2026.